Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label VELCADE in previously treated advanced bronchioloalveolar carcinoma
2004-004648-29Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in bronchioloalveolar carcinoma (BAC) and lung adenocarcinoma with bronchioloalveolar features, sponsored by Janssen Pharmaceutical. Primary endpoint: Objective tumor response rate. Started Apr 2005; status: terminated.
02
Drugs
bortezomib
03
Conditions
bronchioloalveolar carcinoma (BAC)lung adenocarcinoma with bronchioloalveolar features
Beyond the preview
Go deeper on 2004-004648-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004648-29.